NCT06379360 2026-03-19
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
Clinical Trials
936 trialsNCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT04546945 2026-03-18
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Assiut University
Recruiting
NCT05092451 2026-03-18
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06071624 2026-03-18
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Indiana University
Phase 1 Recruiting
NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting
NCT06561360 2026-03-18
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07479927 2026-03-18
PsyCARTkids
Hospital Universitario La Paz
Phase NA Recruiting
NCT03590171 2026-03-17
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 2 Recruiting
NCT06918431 2026-03-17
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT03422731 2026-03-16
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT04628026 2026-03-16
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT05112614 2026-03-16
Role of Gut Microbiome in Cancer Therapy
Mayo Clinic
Recruiting
NCT06325280 2026-03-16
Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease
University of Alberta
Recruiting
NCT06481735 2026-03-16
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06561074 2026-03-16
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03728335 2026-03-13
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT04644016 2026-03-13
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05451979 2026-03-13
HIIT in Pediatric Heart Transplant Recipients (MedBIKEâ„¢)
University of Alberta
Phase NA Recruiting
NCT06055621 2026-03-13
VEN-R DASA
Institut Paoli-Calmettes
Phase 2 Recruiting
NCT06222580 2026-03-13
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06377059 2026-03-13
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Rigshospitalet, Denmark
Phase NA Recruiting
NCT06523556 2026-03-13
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06557421 2026-03-13
STOP VEN
Institut Paoli-Calmettes
Phase 2 Recruiting
NCT06738368 2026-03-13
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT06763341 2026-03-13
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT07218510 2026-03-13
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT07270978 2026-03-13
AML-MDS 001
University of Virginia
Phase 1 Recruiting
NCT01962636 2026-03-12
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Recruiting
NCT02392572 2026-03-12
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT06867289 2026-03-12
DINAMO
Centre Hospitalier Régional Metz-Thionville
Phase NA Recruiting
NCT07325305 2026-03-12
PROTECT
Murdoch Childrens Research Institute
Phase NA Recruiting
NCT03471260 2026-03-11
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05535855 2026-03-11
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
University of Colorado, Denver
Phase 1 Recruiting
NCT05834244 2026-03-11
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04565665 2026-03-10
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05748197 2026-03-10
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06229860 2026-03-10
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
University of California, Irvine
Recruiting
NCT06316856 2026-03-10
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT06343090 2026-03-10
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Beijing GoBroad Hospital
Phase NA Recruiting
NCT06459024 2026-03-10
IMPACT STREAM
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recruiting
NCT06707493 2026-03-10
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital
Phase 2 Recruiting
NCT06890494 2026-03-10
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
Beijing GoBroad Hospital
Phase EARLY_PHASE1 Recruiting
NCT07173166 2026-03-10
CARE-T
Instituto de Investigacion Sanitaria INCLIVA
Phase NA Recruiting
NCT07257419 2026-03-10
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting